Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer where abnormal cells are found in the milk ducts but have not spread beyond the duct. While it is considered the earliest stage of breast cancer, understanding the progression rate of DCIS is crucial for effective management and prevention of its potential spread. In this article, we will delve into some frequently asked questions regarding the progression of DCIS and shed light on the available evidence.

What is the typical progression rate of DCIS?

DCIS is not always predictable in terms of progression. Some cases of DCIS may never progress to invasive breast cancer, while others may progress slowly or rapidly. Research suggests that approximately 20-30% of untreated DCIS cases eventually progress to invasive breast cancer if left untreated over a 10-year period. However, it is important to note that not all cases will follow the same pattern, and individual factors play a significant role in determining the rate of progression.

What factors can influence the progression of DCIS?

Various factors can impact the progression of DCIS, including:

a) Nuclear grade: The nuclear grade of DCIS cells, which evaluates their abnormality, is often a strong predictor of progression. High-grade DCIS is more likely to progress rapidly than low-grade DCIS.

b) Tumor size: Larger areas of DCIS are associated with a higher risk of progression. However, it is worth noting that the size alone is not the sole determinant but rather an indicator that needs to be considered alongside other factors.

c) Age: Younger women diagnosed with DCIS tend to have a higher risk of progression. This might be due to hormonal influences or biological differences.

d) Genetic factors: Some genetic mutations, such as in the BRCA1 and BRCA2 genes, may increase the risk of progression from DCIS to invasive breast cancer.

How is the risk of progression assessed?

To estimate the risk of progression, medical professionals often use various scoring systems, such as the Van Nuys Prognostic Index (VNPI) or the Nottingham Grading System. These scoring systems consider factors such as nuclear grade, tumor size, and age to estimate the likelihood of progression and help guide treatment decisions.

Can any measures be taken to prevent DCIS progression?

While complete prevention of DCIS progression is not guaranteed, several measures can help reduce the risk:

a) Active surveillance: For patients with low-risk DCIS, active surveillance may be an option. Regular monitoring through mammograms and physical examinations allows doctors to promptly intervene if signs of progression are observed.

b) Surgery: Lumpectomy or mastectomy to remove the abnormal cells can help prevent progression. Radiation therapy may also be recommended in certain cases to reduce the risk of recurrence.

c) Hormonal therapy: In some cases, DCIS cells are hormone-receptor positive, meaning they grow in response to hormones. Hormonal therapy, such as tamoxifen or aromatase inhibitors, can reduce the risk of progression by blocking the hormones’ effects.

The progression rate of DCIS varies greatly among individuals due to a multitude of factors. Identifying high-risk cases is essential to prevent the progression to invasive breast cancer. Regular monitoring, surgical interventions, and hormonal therapies are potential options to manage and reduce the risk of DCIS progression. Consulting with healthcare providers and developing personalized treatment plans is crucial for patients diagnosed with DCIS, taking into consideration individual characteristics and preferences.

Quest'articolo è stato scritto a titolo esclusivamente informativo e di divulgazione. Per esso non è possibile garantire che sia esente da errori o inesattezze, per cui l’amministratore di questo Sito non assume alcuna responsabilità come indicato nelle note legali pubblicate in Termini e Condizioni
Quanto è stato utile questo articolo?
0Vota per primo questo articolo!